Research graph
References from A partial response to atezolizumab in alveolar soft part sarcoma with near-complete resolution of extensive pulmonary metastases: a case report. Local targets link to admitted publications; unresolved targets remain external evidence.
Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities
10.1002/cncr.33618 · 2021 · External reference
Alveolar soft part sarcoma
10.1002/1097-0142(20010201)91:3<585::aid-cncr1038>3.0.co;2-0 · 2001 · External reference
Advances in treatment of alveolar soft part sarcoma: An updated review
10.1093/jjco/hyad102 · 2023 · External reference
The current management of alveolar soft part sarcomas
10.1097/md.0000000000026805 · 2021 · External reference
The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25
10.1038/sj.onc.1204074 · 2001 · External reference
ASPSCR1::TFE3 drives alveolar soft part sarcoma by inducing targetable transcriptional programs
10.1158/0008-5472.can-23-2115 · 2024 · External reference
Complete response to nivolumab and ipilimumab after pazopanib discontinuation in a seven-year-old girl with alveolar soft part sarcoma: A case report and literature review
10.1002/cnr2.70305 · 2025 · External reference
Diagnosis, prognosis, and treatment of alveolar soft-part sarcoma: A review
10.1001/jamaoncol.2018.4490 · 2019 · External reference
Advances in alveolar soft part sarcoma treatment in the era of immunotherapy
10.1016/j.esmorc.2025.100002 · 2025 · External reference
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
10.1016/j.ejca.2008.10.026 · 2009 · External reference
iRECIST: Guidelines for response criteria for use in trials testing immunotherapeutics
10.1016/s1470-2045(17)30074-8 · 2017 · External reference
Alveolar soft part sarcoma: Progress toward improvement in survival? A population-based study
10.1186/s12885-022-09968-5 · 2022 · External reference
Atezolizumab for advanced alveolar soft part sarcoma
10.1056/nejmoa2303383 · 2023 · External reference
Clinical, immunological, and genomic findings of atezolizumab in advanced alveolar soft part sarcoma: A phase II trial (ALBERT trial/NCCH1907)
10.1016/j.ejca.2025.116104 · 2026 · External reference
Gamma Knife radiosurgery as a therapeutic strategy for intracranial sarcomatous metastases
10.1016/j.ijrobp.2009.02.007 · 2010 · External reference
Necrosis of a skin autograft after short-term treatment with sunitinib in a 14-year-old girl with metastatic alveolar soft part sarcoma of the thigh
10.1055/s-0030-1249093 · 2010 · External reference
Prognostic factors in alveolar soft part sarcoma: A SEER analysis
10.1002/jso.24183 · 2016 · External reference
Characterization of alveolar soft part sarcoma using a large national database
10.1016/j.surg.2020.06.007 · 2020 · External reference
Immune checkpoint inhibitors in sarcomas: In quest of predictive biomarkers
10.1038/labinvest.2017.128 · 2018 · External reference
Positive tumor response to combined checkpoint inhibitors in a patient with refractory alveolar soft part sarcoma: A case report
10.1200/jgo.2017.009993 · 2017 · External reference
TGF-β activation and function in immunity
10.1146/annurev-immunol-032713-120257 · 2014 · External reference
Atezolizumab for alveolar soft part sarcoma: A clinical trial update
10.1200/jco-25-02811 · 2026 · External reference
CTLA-4 and PD-1 pathway blockade: Combinations in the clinic
10.3389/fonc.2014.00385 · 2015 · External reference
Immunological mechanisms behind anti-PD-1/PD-L1 immune checkpoint blockade: Intratumoral reinvigoration or systemic induction
10.3390/biomedicines12040764 · 2024 · External reference
PD-L1 immunohistochemistry comparability study in real-life clinical samples: Results of blueprint phase 2 project
10.1016/j.jtho.2018.05.013 · 2018 · External reference
Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas
10.1371/journal.pone.0082870 · 2013 · External reference
Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment
10.1016/j.humpath.2014.11.001 · 2015 · External reference
Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma
10.1186/s12885-016-2451-6 · 2016 · External reference
Immunotherapy in sarcoma: Current data and promising strategies
10.1200/edbk_432234 · 2024 · External reference
Dramatic response of a PD-L1–positive advanced angiosarcoma of the scalp to pembrolizumab
10.1200/po.17.00107 · 2018 · External reference
Case report: A PD-L1-positive patient with pleomorphic rhabdomyosarcoma achieving an impressive response to immunotherapy
10.3389/fimmu.2022.815598 · 2022 · External reference
Natural history and treatment sensitivity of alveolar soft part sarcoma: A national multicenter analysis from the French sarcoma group
10.1016/j.ejca.2026.116590 · 2026 · External reference
